DrugPatentWatch vs Make Opinion Next
DrugPatentWatch
drugpatentwatch.comMake Opinion Next
makeopinion.comSide by side
| Figure | DrugPatentWatch | Make Opinion Next |
|---|---|---|
| Price from | $666.67/mo | €500/mo |
| Free plan | — | Yes |
| Free trial | — | — |
| Open source | — | — |
| Web | Yes | Yes |
| API | Yes | Yes |
| Plans published | 6 | 5 |
| Spec score · Market Research Software | 7.8 (#18) | 8.3 (#12) |
| Audience | The maker says the platform is used by pharmaceutical and biotech companies, generic manufacturers, biosimilar developers, investors, law firms, consultants, researchers, and healthcare institutions. | The maker identifies insights and marketing teams, product and UX teams, startups, researchers and students as intended users. |
| Coverage | The pricing page lists active and expired patents in 134 countries, regulatory protections, and exclusivities. | The platform reaches more than 10 million respondents in over 150 countries. |
| Headquarters | Washington, DC, United States | Berlin, Germany |
| Purpose | DrugPatentWatch organizes pharmaceutical patent and regulatory information to help users understand branded drugs, generic entry, and pharmaceutical exclusivity. | Make Opinion Next combines survey design, respondent access, fieldwork and results in one market research platform. |
| Support | The contact page lists thinkBiotech LLC at 1133 15th Street NW, 12th Floor, Washington, DC 20005, and provides a phone number and contact form. | Self-serve includes free expert support for study design, scripting, fieldwork and results. |
Plans
DrugPatentWatch
- Professional trial$499, paid once
- Starter$1,000 a month
- Professional$3,000 a month
- Starter$8,000 a year
- Professional$24,000 a year
- EnterprisePriced on request
Make Opinion Next
- Self-ServeFree
- Scripted€500 a month
- Scripted€500, paid once
- Managed ServicesPriced on request
- ScriptedPriced on request
In their own words
DrugPatentWatch
DrugPatentWatch has no write-up on Specifiction yet; its figures are above.
Make Opinion Next
Make Opinion Next has no write-up on Specifiction yet; its figures are above.